111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR

Journal of Nuclear Medicine

Volumn 41, Issue 3, 2000, Pages 429-438

  Reilly, Raymond M ^b   Kiarash, Reza ^b   Cameron, Ross G ^b   Porlier, Nicole ^b   Sandhu, Jasbir ^b   Hill, Richard P ^b   Vallis, Katherine ^b   Hendler, Aaron ^b   Gariépy, Jean ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE

Author keywords

111In; Auger electrons; Breast cancer; Epidermal growth factor; Epidermal growth factor receptor

Indexed keywords

CELL SURFACE RECEPTOR; CREATININE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; INDIUM 111; PENTETATE INDIUM IN 113M; INDIUM;

ARTICLE; BREAST CANCER; CELL NUCLEUS TRANSPLANTATION; CONTROLLED STUDY; ELECTRON THERAPY; HUMAN; HUMAN CELL; INTERNALIZATION; ISOTOPE LABELING; PRIORITY JOURNAL; RADIOACTIVITY; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL CULTURE; FEMALE; FLUORESCENCE MICROSCOPY; IN VITRO STUDY; KIDNEY; LIVER; METABOLISM; MOUSE; PATHOLOGY; RADIATION DOSE; RADIOTHERAPY;

ANIMALS; BREAST NEOPLASMS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; INDIUM RADIOISOTOPES; KIDNEY; LIVER; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; RADIATION DOSAGE; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0033622156     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Reilly RM. Radioimmunotherapy of malignancies. Clin Pharm. 1991;10:359-375.
2. Adelstein SJ. The Auger process: a therapeutic promise. AJR. 1993;160:707-713.
3. Hofer KG, Harris CR, Smith MJ. Radiotoxicity of intracellular Ga-67, I-125 and H-3: nuclear versus cytoplasmic radiation effects in murine L1210 leukemia cells. Int J Radiat Biol Relat Stud Phys Chem Med. 1975;28:225-241.
4. 125I-labeled DNA-binding compound that induces double-stranded DNA breaks. Cancer Res. 1979;39:3244-3247.
5. McLean JR, Blakey DH, Douglas GR, Bayley J. The Auger electron dosimetry of indium-111 in mammalian cells in vitro. Radiat Res. 1989;119:205-218.
6. 125I in mammalian cells. Radiat Res. 1987;111:305-318.
7. 3HTdR. Radiat Res. 1976;67:332-343.
8. 125I]iodo-2′-deoxyuridine after intravesical infusion in patients with bladder cancer. J Nucl Med. 1996;37(suppl):16S-18S.
9. 123]iodo-2′-deoxyuridine in a patient with a brain tumor. J Nucl Med. 1996;37(suppl):19S-21S.
10. 125]-iodo-2′deoxyuridine in the treatment of colorectal cancer metastatic to the liver. J Nucl Med. 1996;37(suppl):25S-29S.
11. Kraal G, Geldorf AA. Radiotoxicity of indium-111. J Immunol Methods. 1979;31:193-195.
12. Ten Berge RJM, Natarajan AT, Hardeman MR, et al. Labeling with In-111 has detrimental effects on human lymphocytes: concise communication. J Nucl Med. 1983;24:615-620.
13. 111In]oxine labeling of human tumor cell line (HeLa S3). J Labelled Compd Radiopharm. 1979;16:116-117.
14. Haigler H, Ash JF, Singer SJ, Cohen S. Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431. Proc Natl Acad Sci USA. 1978;75:3317-3321.
15. Mendelsohn J. Growth factor receptors as targets for antitumor therapy with monoclonal antibodies. In: Mendelsohn J, Waldmann H, eds. Monoclonal Antibody Therapy. Basel, Switzerland: Karger; 1988:147-160.
16. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
17. 1-octreotide. J Nucl Med. 1996;37:2002-2006.
18. Krenning EP, Valkema R, Kooij PPM, et al. Peptide receptor radionuclide therapy with [indium-111-DTPA-D-Phe]-octreotide [abstract]. J Nucl Med. 1997;38(suppl): 47P.
19. Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev. 1992;13:3-17.
20. Fields Jones SM, Burris HA III, Herfindal ET, Gourley DR. Breast cancer. In: Herfindal ET, Gourleey DR, eds. Textbook of Therapeutics: Drug and Disease Management. 6th ed. Baltimore, MD: Williams & Wilkins; 1996:1533-1547.
21. Reilly RM, Gariëpy J. Factors influencing the sensitivity of tumor imaging using a receptor-binding radiopharmaceutical. J Nucl Med. 1998;39:1037-1042.
22. Olsson P, Lindstrom A, Carlsson J. Internalization and excretion of epidermal growth factor-dextran-associated radioactivity in cultured human squamous-carcinoma cells. Int J Cancer. 1994;56:529-537.
23. Rakowicz-Szulczynska EM, Rodeck U, Herlyn M, Koprowski H. Chromatin binding of epidermal growth factor, nerve growth factor, and platelet-derived growth factor in cells bearing the appropriate surface receptors. Proc Natl Acad Sci USA. 1986;83:3728-3732.
24. Filmus J, Pollak MN, Cailleau R, Buick RN. A human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem Biophys Res Commun. 1985;128:898-905.
25. Dunn WA, Hubbard AL. Receptor-mediated endocytosis of epidermal growth factor by hepatocytes in the perfused rat liver: ligand and receptor dynamics. J Cell Biol. 1984;98:2148-2159.
26. Fisher DA, Salido EC, Barajas L. Epidermal growth factor and the kidney. Annu Rev Physiol. 1989;51:67-80.
27. Osborne CK, Hamilton B, Nover M. Receptor binding and processing of epidermal growth factor by human breast cancer cells. J Clin Endocrinol Metab. 1982;55:86-93.
28. Holt SJ, Alexander P, Inman CB, Davies DE. Ligand-induced translocation of epidermal growth factor receptor to the nucleus of NR6/HER fibroblasts is serum dependent Exp Cell Res. 1995;217:554-558.
29. Raper SE, Burwen SJ, Barker ME, Jones AL. Translocation of epidermal growth factor to the hepatocyte nucleus during rat liver regeneration. Gastroenterology. 1987;92:1243-1250.
30. Rakowicz-Szulczynska EM, Otwiaska D, Rodeck U, Koprowski H. Epidermal growth factor (EGF) and monoclonal antibody to cell EGF surface receptor bind to the same chromatin receptor. Arch Biochem Biophys. 1989;268:456-464.
31. Johnson LK, Vlodavsky I, Baxter JD, Gospodarowicz D. Nuclear accumulation of epidermal growth factor in cultured rat pituitary cells. Nature. 1980;28:340-343.
32. Laduron PM. Genomic pharmacology: more intracellular sites for drug action. Biochem Pharmacol. 1992;44:1233-1242.
33. Faraggi M, Gardin I, de Labriolle-Vaylet C, Moretti J-L, Bok BD. The influence of tracer localization on the electron dose rate delivered to the cell nucleus. J Nucl Med. 1994;35:113-119.
34. Goddu SM, Howell RW, Rao DV. Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med. 1994;35:303-316.
35. 198Au). Int J Radiat Biol. 1969;14:497-515.
36. Hebard DW, Jackson KL, Christensen GM. The chronological development of late radiation injury in the liver of the rat. Radiat Res. 1980;81:441-454.
37. Waltz TM, Malm C, Nishikawa BK, Wasteson A. Transforming growth factor-alpha (TGF-alpha) in human bone marrow: demonstration of TGF-alpha in erythroblasts and eosinophilic precursor cells and of epidermal growth factor receptors in blastlike cells of myelomonocytic origin. Blood. 1995;85:2385-2392.
38. Reilly RM, Kiarash R, Sandhu J, Gariépy J. A comparison of the native peptide ligand and a monoclonal antibody against the epidermal growth factor receptor (EGFR) for imaging human breast cancer [abstract]. J Nucl Med. 1998;39:77P.
39. Reubi JC, Waser B, Foekens JA, Klijn JGM, Lamberts SWJ, Laissue J. Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors. Int J Cancer. 1990;46:416-420.
40. 125I]iodo-estradiol in cultured MCF-7 human breast cancer cells. J Natl Cancer Inst. 1989;81:437-440.